colorectal liver metastases
Conditions
Interventions
None listed
Sponsors
Siemens Molecular Imaging Biomarker Research
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Patient is >18 years and male or female of any race / ethnicity • Patient provides written informed consent and willing to comply with protocol requirements • Patient must be scheduled to receive chemotherapy treatment(s) plus Avastin® for their cancer care; treatment management will be made by treating medical oncologists (According to the package insert for Avastin®, it is administered as an IV infusion every 3 weeks for non-squamous non-small cell lung cancer, and every 2 weeks for metastatic breast cancer, colon or rectum cancer) • Patient will be scheduled to have a clinical [F-18] FDG-PET/CT or diagnostic CT pretreatment, and after the fourth but before the fifth Avastin® treatment
Exclusion criteria
Exclusion criteria: • Patient is not capable of complying with study procedures • Female patient is pregnant or nursing • Patient has a severe hepatic or renal disease as defined by previous medical history or abnormal renal and hepatic functions determined by lab results not within the following ranges, or in the opinion of the Investigator, the values are not acceptable for the patient to be included: o AST (SGOT)/ALT (SGPT)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective for this study is: • To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response to Avastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full course of treatment is completed | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary objective for this study is: • To gain experience with [F-18]RGD-K5 PET/CT in order to improve the study design and conduct of future studies | — |
Countries
Netherlands
Outcome results
None listed